Omeros Corporation - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Omeros Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Omeros Corporation - Product Pipeline Review - 2016', provides an overview of the Omeros Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Omeros Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Omeros Corporation
- The report provides overview of Omeros Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Omeros Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Omeros Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Omeros Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Omeros Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Omeros Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Omeros Corporation Snapshot 6
Omeros Corporation Overview 6
Key Information 6
Key Facts 6
Omeros Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Omeros Corporation - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Omeros Corporation - Pipeline Products Glance 16
Omeros Corporation - Late Stage Pipeline Products 16
Omeros Corporation - Clinical Stage Pipeline Products 17
Omeros Corporation - Early Stage Pipeline Products 18
Omeros Corporation - Drug Profiles 22
OMS-721 22
OMS-405 24
OMS-824 25
Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders 26
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications 28
OMS-527 30
OMS-616 32
OMS-906 34
Small Molecule to Agonize GPR52 for Schizophrenia 35
Small Molecule to Agonize PTH-1R for Osteoporosis 36
Small Molecule to Antagonize GPR101 for Appetite Disorders 37
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders 38
Small Molecule to Antagonize GPR139 for Motor Disorders 39
Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy 40
Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders 41
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders 42
Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia 43
Small Molecule to Antagonize GPR182 for Pancreatic Cancer 44
Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer 45
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia 46
Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia 47
Small Molecule to Antagonize GPR31 for Anxiety Disorders 48
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes 49
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia 50
Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia 51
Small Molecule to Antagonize GPR87 for Oncology 52
Small Molecule to Antagonize NMUR2 for Pain 53
Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders 55
Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma 56
Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders 57
Small Molecule to Target GPR132 for Cardiovascular Diseases 58
Small Molecule to Target GPR135 59
Small Molecule to Target GPR141 for Respiratory and Immune Disorders 60
Small Molecule to Target GPR150 for Ovarian Cancer 61
Small Molecule to Target GPR151 for CNS Diseases 62
Small Molecule to Target GPR153 for Schizophrenia 63
Small Molecule to Target GPR162 for Neuropsychiatric Disorders 64
Small Molecule to Target GPR171 for Eating and Hematological Disorders 65
Small Molecule to Target GPR174 for Immunology, Neurology and Oncology 66
Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections 67
Small Molecule to Target GPR21 for Obesity and Diabetes 68
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis 69
Small Molecule to Target GPR25 for Arterial Stiffness 70
Small Molecule to Target GPR32 for Acute Inflammation 71
Small Molecule to Target GPR37 for Parkinson's Disease 72
Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy 73
Small Molecule to Target GPR45 74
Small Molecule to Target GPR50 for CNS and Metabolic Disorders 75
Small Molecule to Target GPR63 for Autism 76
Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders 77
Small Molecule to Target GPR80 for Hepatocellular Carcinoma 78
Small Molecule to Target GPR82 for Appetite Disorders and Body Weight 79
Small Molecule to Target GPR83 for CNS and Immunological Disorders 80
Small Molecule to Target LGR4 for Oncology and Osteoporosis 81
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma 82
Small Molecule to Target LGR6 for Dermatology 83
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer 84
Small Molecule to Target MRGE for Pain 85
Small Molecule to Target MRGF 86
Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis 87
Small Molecule to Target OPN5 88
Small Molecules to Agonize GPR61 for Eating Disorder 89
Small Molecules to Target GPR146 for Metabolic Disorders 90
Omeros Corporation - Pipeline Analysis 91
Omeros Corporation - Pipeline Products by Target 91
Omeros Corporation - Pipeline Products by Route of Administration 94
Omeros Corporation - Pipeline Products by Molecule Type 95
Omeros Corporation - Pipeline Products by Mechanism of Action 96
Omeros Corporation - Recent Pipeline Updates 98
Omeros Corporation - Dormant Projects 107
Omeros Corporation - Discontinued Pipeline Products 108
Discontinued Pipeline Product Profiles 108
Omeros Corporation - Locations And Subsidiaries 109
Head Office 109
Other Locations & Subsidiaries 109
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111

List of Tables

Omeros Corporation, Key Information 10
Omeros Corporation, Key Facts 10
Omeros Corporation - Pipeline by Indication, 2016 12
Omeros Corporation - Pipeline by Stage of Development, 2016 18
Omeros Corporation - Monotherapy Products in Pipeline, 2016 19
Omeros Corporation - Phase III, 2016 20
Omeros Corporation - Phase II, 2016 21
Omeros Corporation - Preclinical, 2016 22
Omeros Corporation - Discovery, 2016 25
Omeros Corporation - Pipeline by Target, 2016 95
Omeros Corporation - Pipeline by Route of Administration, 2016 98
Omeros Corporation - Pipeline by Molecule Type, 2016 99
Omeros Corporation - Pipeline Products by Mechanism of Action, 2016 101
Omeros Corporation - Recent Pipeline Updates, 2016 102
Omeros Corporation - Dormant Developmental Projects,2016 111
Omeros Corporation - Discontinued Pipeline Products, 2016 112
Omeros Corporation, Subsidiaries 113